Thus, the PSA test used to screen for prostate cancer is considered a preference sensitive decision; meaning it does not only depend on what is best from a medical point of view, but also taking into account patient preferences; i.e., the values a patient attaches to the advantages and disadvantages of that option [4]. This evidence concerns the gene KLK3 and Familial prostate cancer.